advertisement
Abstract #47509 Published in IGR 13-4
Subconjunctival Bevacizumab versus Mitomycin C Adjunctive to Trabeculectomy
Nilforushan N; Yadgari M; Kish SK; Nassiri NAmerican Journal of Ophthalmology 2011;
Purpose: To compare the outcome of trabeculectomy with subconjunctival bevacizumab with that of trabeculectomy with mitomycin C (MMC). Design: Prospective, randomized, comparative study. Methods: Thirty-six eyes from 34 patients with uncontrolled glaucoma were enrolled. Eighteen eyes underwent trabeculectomy with subconjunctival bevacizumab injection (2.5 mg/0.1 mL), and 18 eyes underwent trabeculectomy with MMC (0.02% for 3 minutes). The outcome measures were the best-corrected visual acuity, intraocular pressure (IOP), number of IOP-lowering medications, complications, and bleb morphologic features (based on the Indiana Bleb Appearance Grading Scale). Results: The mean follow-up times for the MMC and bevacizumab groups were 7.8 (plus or minus) 2.2 months and 7.4 (plus or minus) 24 months, respectively (P = .62). The mean preoperative IOP in the bevacizumab group improved from 21.9 (plus or minus) 7.9 mm Hg with 2.7 (plus or minus) 0.8 antiglaucoma medications to 13.6 (plus or minus) 3.2 mm Hg with 0.2 (plus or minus) 0.5 antiglaucoma medications at the last visit (P < .001 and P < .001, respectively). The mean preoperative IOP in the MMC group improved from 23.3 (plus or minus) 4.9 mm Hg with 2.6 (plus or minus) 0.7 antiglaucoma medications to 9.6 (plus or minus) 2.7 mm Hg with no antiglaucoma medications at the final visit (P < .001 and P < .001, respectively). There was a statistically significant difference in the IOP between the 2 groups at the last visit (P < .001). The cumulative probabilities of total success at the last follow-up according to Kaplan-Meier analysis were 100% and 94.4% in bevacizumab and MMC groups, respectively (P = .32, log-rank test). Conclusions: Adjunctive subconjunctival bevacizumab with trabeculectomy is effective in controlling the IOP profile; however, its effect is less prominent than that of MMC. (copyright) 2011 Elsevier Inc. All rights reserved.
N. Nilforushan. Ophthalmic Research Center, Rassoul Akram Hospital, Department of Ophthalmology, Tehran University o, . Email: naveednil@yahoo.com
Classification:
12.8.10 Woundhealing antifibrosis (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
